{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:38:02Z","timestamp":1792521482156,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jbspin.2022.105464","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T12:12:40Z","timestamp":1663675960000},"page":"105464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis"],"prefix":"10.1016","volume":"90","author":[{"given":"Carla","family":"G.S. Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus","family":"S.R. Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perceval D.","family":"Sampaio-Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5766-6802","authenticated-orcid":false,"given":"Julio","family":"C.B. Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-9699","authenticated-orcid":false,"given":"Cl\u00e1udia","family":"G. Schainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celio R.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Y.","family":"Shimabuco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia E.","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-405X","authenticated-orcid":false,"given":"Emily","family":"F.N. Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"G. Pasoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"V.K. Kupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"K. Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"S.R. Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00f3vis A.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Medeiros-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-4681","authenticated-orcid":false,"given":"Eloisa","family":"Bonfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2022.105464_bib0170","series-title":"Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac: interim guidance, first issued 24 May 2021, updated 21 October 2021, updated 15 March 2022","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.jbspin.2022.105464_bib0175","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0180","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jbspin.2022.105464_bib0185","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0190","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0195","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2022.105464_bib0200","doi-asserted-by":"crossref","unstructured":"Silva CA, Medeiros-Ribeiro AC, Kupa LVK. Anti-SARS-CoV-2 immunogenicity decay and incident cases six months after Sinovac-CoronaVac inactivated vaccine in autoimmune rheumatic disease patients: phase 4 prospective trial, 23 November 2021, PREPRINT (version 1) available at research square: doi: 10.21203\/rs.3.rs-1054476\/v1.","DOI":"10.21203\/rs.3.rs-1054476\/v1"},{"key":"10.1016\/j.jbspin.2022.105464_bib0205","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/annrheumdis-2021-222096","article-title":"Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases","volume":"81","author":"Aikawa","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0210","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2021-221735","article-title":"Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis","volume":"81","author":"Medeiros-Ribeiro","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0215","doi-asserted-by":"crossref","unstructured":"Yuki EFN, Borba EF, Pasoto, SG, et al. Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus. Arthritis Care Res;74:562\u2013571.","DOI":"10.1002\/acr.24824"},{"key":"10.1016\/j.jbspin.2022.105464_bib0220","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 DimRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0225","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0230","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105464_bib0235","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/rheumatology\/kes202","article-title":"TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients","volume":"51","author":"Fran\u00e7a","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105464_bib0240","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/annrheumdis-2021-221347","article-title":"Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis","volume":"81","author":"Simader","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0245","doi-asserted-by":"crossref","first-page":"462","DOI":"10.14309\/ajg.0000000000001619","article-title":"Factors affecting initial humoral immune response to SARS-CoV-2 vaccines among patients with inflammatory bowel diseases","volume":"117","author":"Kappelman","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jbspin.2022.105464_bib0250","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gutjnl-2021-324388","article-title":"Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jbspin.2022.105464_bib0255","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","article-title":"Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study","volume":"4","author":"Wieske","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105464_bib0260","first-page":"100154","article-title":"Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study","volume":"6","author":"Cerqueira-Silva","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.jbspin.2022.105464_bib0265","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralising antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jbspin.2022.105464_bib0270","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jbspin.2022.105464_bib0275","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0280","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/annrheumdis-2021-220862","article-title":"Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis","volume":"80","author":"Bugatti","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0285","article-title":"Inactivated SARS-CoV-2 vaccine in primary Sj\u00f6gren's syndrome: humoral response, safety, and effects on disease activity","volume":"1\u201311","author":"Pasoto","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105464_bib0290","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1016\/S2665-9913(21)00222-8","article-title":"Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies","volume":"3","author":"Boekel","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105464_bib0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0300","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","volume":"80","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0305","doi-asserted-by":"crossref","first-page":"811829","DOI":"10.3389\/fmed.2022.811829","article-title":"Vaccination for SARS-CoV-2 in patients with psoriatic arthritis: can therapy affect the immunological response?","volume":"9","author":"Benucci","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jbspin.2022.105464_bib0310","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1515\/jbcpp-2021-0349","article-title":"Can sulfasalazine as an old drug with immunomodulatory and anti-inflammatory effects be effective in COVID-19?","volume":"33","author":"Ghasemnejad-Berenji","year":"2021","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10.1016\/j.jbspin.2022.105464_bib0315","unstructured":"Meiruze SF, National Health Vigilance Agency (ANVISA), Brazil. Process 25351.931900\/2021-84. 2021."},{"key":"10.1016\/j.jbspin.2022.105464_bib0320","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/annrheumdis-2021-222096","article-title":"Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases","volume":"81","author":"Aikawa","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105464_bib0325","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S2665-9913(21)00328-3","article-title":"Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses","volume":"4","author":"Schmiedeberg","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105464_bib0330","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/annrheumdis-2021-221490","article-title":"Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry","volume":"81","author":"Machado","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:29:22Z","timestamp":1761150562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X22001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1297319X22001245"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105464","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105464"}}